Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian Indices End Marginally Lower; Realty Stocks Witness Losses
Thu, 3 May Closing

After witnessing volatile trades during the day, Indian share markets ended their session marginally lower. Losses were largely seen in the realty sector, capital goods sector and IT sector, while metal stocks ended the day higher.

At the closing bell, the BSE Sensex stood lower by 73 points (down 0.2%) and the NSE Nifty closed lower by 38 points (down 0.4%). The BSE Mid Cap index ended the day down by 1.2%, while the BSE Small Cap index ended the day down by 0.8%.

Asian stock markets finished on a negative note as of the most recent closing prices. The Hang Seng was down 1.3% and the Nikkei stood lower by 0.2%.

The rupee was trading at 66.56 to the US$ at the time of writing.

In the news from pharma sector, Biocon share price witnessed selling pressure today on reports of US Food and Drug Administration (USFDA) observations of the company's Bangalore facility.

The company's Bangalore sterile drug product facility has got seven observations from USFDA and six observations from the European regulator.

Biocon share price ended the day down by 5.5% on the BSE.

Speaking of pharma stocks, did you know the BSE Healthcare Index is down 20% over the past three years? During the same period, the BSE Sensex is up 21%.

And this was a sector they called 'evergreen'.

Have Investors boarded a plane that's about to crash? Or is it just turbulence on the way to a smooth and safe landing?

Here's what we wrote about the same in one of the recent editions of The 5 Minute WrapUp:

  • It's important to understand the core issues. Regulatory problems for pharma companies have increased over the past few years. The frequency of visits as well as quality expectations have increased a lot.

    The intensity of competition has also increased. Faster approvals of drugs have led to price erosion for generic players.

    While we expect the pain to continue in the short-term, the long-term picture still looks bright.

    Stricter norms and pricing pressure will ensure only quality players remain. Companies with strong R&D facilities and quality compliant plants will have an edge over the others.

    Those are the only pharma stocks you should be looking at.

    And even among those, only three of them offer enough margin of safety today.

You can access these safe stocks here.

In other news, PC Jeweller share price was in focus today. At the closing hours, the stock of the company reversed its early losses and rose from the day's low after the management of the company termed reports of arrest of MD and CEO Balram Garg by the CBI as factually incorrect.

PC Jeweller share price ended its trading session up by 9.7% on the BSE today.

In the news from global financial markets, the US Federal Reserve left interest rates unchanged at 1.50-1.75% in its recently held monetary policy meet. While doing so, they also acknowledged that inflation is close to their target without indicating any intention to veer from their gradual path of interest-rate increases.

The central bank also signaled that the gradual path of rate hikes will stay.

Note that Fed officials have indicated that they expect a total of 3 to 4 hikes in 2018. This view was reaffirmed as the central bank said that economic conditions will warrant further gradual increases in the federal funds rate.

The Fed also mentioned that the labour market remains strengthened and economic activity is rising at a moderate rate. It also highlighted that the job gains have been strong in recent months, and the unemployment rate has stayed low.

Note that with the US economy chugging along for many months, the Fed is now gradually easing off the stimulus it provides to the economy by raising interest rates to more normal levels.

Federal Reserve Rate Hike in the Past 3 Years


How does a US interest rate hike affect Indian investors?

The instant effect is foreign money moving out of India's vaults. This means a slight correction in the share market in India, albeit temporarily.

While this might provide a good buying opportunity in long-term stocks, the main thing to look forward would be capex and earnings trends.

In the end, Indian investors are better off staying informed about the corporate earnings revival than Fed rate hikes.

It is also worthwhile to note that the Indian stock market has done relatively well during the last period of rate hikes by the US Fed.

Take 2003-2006 for example...

Between 2003 and 2006, the US Fed rate moved from 1% to 5.25%.

Despite this, the Sensex rose from 3,500 levels to more than 10,000 during the same period. This increase was supported by strong earnings growth.

So, in the long term, rate hikes (triggered by economic growth) have proved good for the Indian markets. In fact, earnings growth is at the heart of Tanushree's prediction of Sensex 100,000.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian Indices End Marginally Lower; Realty Stocks Witness Losses". Click here!